2,2-difluoro-3-methoxypropan-1-ol | 1247089-57-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代醇
• 英文名称: 2,2-difluoro-3-methoxypropan-1-ol
• 英文别名: 2,2-Difluoro-3-methoxypropan-1-ol
• CAS: 1247089-57-1
• 化学式: C₄H₈F₂O₂
• 分子量: 126.103
• InChiKey: CVPCFINYDBWLCG-UHFFFAOYSA-N

物化性质

• 沸点：
  190.7±35.0 °C(Predicted)
• 密度：
  1.152±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,2-difluoro-3-methoxypropan-1-ol 、 2-(propylsulfanyl)-3-[4-(2,2,2-trifluoroethoxy)phenyl]pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 5.17h， 以8 mg的产率得到2-(2,2-difluoro-3-methoxypropoxy)-3-[4-(2,2,2-trifluoroethoxy)phenyl]pyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione
  参考文献：
  名称：

  FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF

  摘要：

  本发明提供了一种化合物，用于预防或治疗与前列腺素相关的疾病，如动脉粥样硬化、动脉血栓形成、糖尿病、肥胖、哮喘、发热、疼痛、癌症、风湿病、骨关节炎、特应性皮炎等，并具有优越的药理作用、理化性质等。本发明涉及一种由以下式表示的化合物：其中每个符号如规范中定义的那样，或其盐。

  公开号：

  US20130131050A1
• 作为产物：
  描述：

  t-Butyl(2,2-difluoro-3-methoxypropoxy)dimethylsilane 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 2,2-difluoro-3-methoxypropan-1-ol
  参考文献：
  名称：

  3,4-Diarylpiperidines as potent renin inhibitors

  摘要：

  The discovery and SAR of a series of potent renin inhibitors possessing a novel 3,4-diarylpiperidine scaffold are described herein. The resulting compound 38 exhibit low nanomolar plasma renin IC50, had a clean CYP 3A4 profile and displayed micromolar affinity for the hERG channel. Furthermore, it was found to be efficacious in the double transgenic rat hypertension model and show good to moderate oral bioavailability in two animal species. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.044

文献信息

• RENIN INHIBITORS
  申请人：McKay Daniel J.

  公开号：US20120035214A1

  公开（公告）日：2012-02-09

  The present invention relates to biaryl piperidine-based renin inhibitor compounds, and their use in treating cardiovascular events and renal insufficiency.

  本发明涉及基于联苯哌啶的肾素抑制剂化合物及其在治疗心血管事件和肾功能不全中的应用。
• Substituted pyrido[2,3-d]pyrimidines as delta-5-desaturase inhibitors
  申请人：Matsunaga Nobuyuki

  公开号：US09023858B2

  公开（公告）日：2015-05-05

  The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. The present invention relates to a compound represented by the following formula: wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种化合物，用于预防或治疗与前列腺素相关的疾病，如动脉粥样硬化、动脉血栓形成、糖尿病、肥胖症、哮喘、发热、疼痛、癌症、风湿病、骨关节炎、特应性皮炎等，具有优越的药理作用、物理化学性质等。本发明涉及一种化合物，其表示如下式：其中每个符号如规范中所定义，或其盐。
• FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
  申请人：Matsunaga Nobuyuki

  公开号：US20130131050A1

  公开（公告）日：2013-05-23

  The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. The present invention relates to a compound represented by the following formula: wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种化合物，用于预防或治疗与前列腺素相关的疾病，如动脉粥样硬化、动脉血栓形成、糖尿病、肥胖、哮喘、发热、疼痛、癌症、风湿病、骨关节炎、特应性皮炎等，并具有优越的药理作用、理化性质等。本发明涉及一种由以下式表示的化合物：其中每个符号如规范中定义的那样，或其盐。
• 3,4-Diarylpiperidines as potent renin inhibitors
  作者：Patrick Lacombe、Mélissa Arbour、Renée Aspiotis、Elizabeth Cauchon、Austin Chen、Daniel Dubé、Jean-Pierre Falgueyret、Pierre-André Fournier、Michel Gallant、Erich Grimm、Yongxin Han、Hélène Juteau、Suzanna Liu、Christophe Mellon、Yeeman Ramtohul、Daniel Simard、René St-Jacques、Gavin Chit Tsui

  DOI：10.1016/j.bmcl.2012.01.044

  日期：2012.3

  The discovery and SAR of a series of potent renin inhibitors possessing a novel 3,4-diarylpiperidine scaffold are described herein. The resulting compound 38 exhibit low nanomolar plasma renin IC50, had a clean CYP 3A4 profile and displayed micromolar affinity for the hERG channel. Furthermore, it was found to be efficacious in the double transgenic rat hypertension model and show good to moderate oral bioavailability in two animal species. (c) 2012 Elsevier Ltd. All rights reserved.